Category Archives: Emerging Markets

Vietnam's Pharma Market "to Rocket" Over Next Six Years

Vietnam’s pharma market in Vietnam is set to increase by $5 billion over the next six years, reaching a net worth of $8 billion by 2020 and representing a Compound Annual Growth Rate (CAGR) of 15.4%, says research firm GlobalData. The company’s  report states that the scarcity of low-priced generic drugs, combined with a belief […]
Also posted in Global | Tagged , , , | Leave a comment

BRIC Nations' "Blossoming Healthcare Budgets" Revive Clinical Trials Opportunities

While some clinical trial sponsors have been driven out of the BRIC nations, a rise in rank for each country — Brazil, Russia, India, China — is expected over the next four years, indicating “blossoming healthcare budgets and markets that are ripe with opportunities for development”. According to a Thomson Reuters report, Overcoming Clinical Challenges in BRIC […]
Also posted in Europe, Global, R&D | Tagged , , , | Leave a comment

Turkey to See Renewed Multinational Investment, Says Report

Turkey is remains a key destination for foreign investment, and the next five years should see renewed interest from pharma multinationals, says a new report by CPhI Worldwide. Although the Turkish government’s price referencing system and fixed euro-lira conversion rate have presented a major obstacle for pharma growth, the report states that these pricing challenges […]
Also posted in Europe, Global, Manufacturing, pricing, R&D | Tagged , , | Leave a comment

What MNCs Can Learn from Generics Companies

In the last three decades, MNCs have contributed greatly to the transfer of knowledge to generic companies in areas such as technology, marketing know-how, working methods, management techniques, R&D, and branding. However, now is the time that MNCs can also learn significantly from generic companies amid the changing global industry landscape. This evolution has enabled […]
Also posted in Guest Blog, Strategy | Tagged , , , , | Leave a comment

Future Brighter for MNCs in Mexico, Says Report

Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma, the market share of generic drugs still makes it difficult for multinationals to materialize their commercial benefit. However, a new report from Business Monitor forecasts that, in the long term, Mexico’s improving private health insurance sector and potentially significant investment from […]
Also posted in Global, healthcare | Tagged , , | Leave a comment
  • Categories

  • Meta